Product Description
a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF. ABT-165 was uniquely engineered using a proprietary dual-variable domain immunoglobulin (DVD-Ig) technology based on its ability to bind and inhibit both DLL4 and VEGF. In vivo, ABT-165 induced significant tumor growth inhibition compared with either parental antibody treatment alone, due, in part, to the disruption of functional tumor vasculature. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29592882/)
Mechanisms of Action: DLL4 Inhibitor, VEGF Inhibitor
Novel Mechanism: Yes
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Colorectal Cancer|Adenocarcinoma
Phase 1: Colorectal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01946074 |
M14-006 | P1 |
Completed |
Colorectal Cancer |
2022-09-28 |
12% |
2023-03-14 |
Primary Endpoints|Treatments |
2017-003669-87 |
2017-003669-87 | P2 |
Terminated |
Adenocarcinoma|Colorectal Cancer |
2020-09-16 |
12% |
2022-03-13 |
Treatments |
NCT03368859 |
M14-064 | P2 |
Terminated |
Colorectal Cancer |
2019-12-18 |
12% |
2024-11-27 |
Primary Endpoints|Treatments |